Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Monte Rosa Therapeutics Inc (GLUE)

Monte Rosa Therapeutics Inc (GLUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 425,758
  • Shares Outstanding, K 61,437
  • Annual Sales, $ 0 K
  • Annual Income, $ -135,350 K
  • EBIT $ -129 M
  • EBITDA $ -123 M
  • 60-Month Beta 1.37
  • Price/Sales 31.21
  • Price/Cash Flow N/A
  • Price/Book 1.94

Options Overview Details

View History
  • Implied Volatility 147.34% ( +26.06%)
  • Historical Volatility 98.52%
  • IV Percentile 61%
  • IV Rank 28.34%
  • IV High 486.85% on 07/19/24
  • IV Low 13.06% on 10/09/24
  • Put/Call Vol Ratio 0.31
  • Today's Volume 47
  • Volume Avg (30-Day) 197
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 5,419
  • Open Int (30-Day) 5,572

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.27
  • Number of Estimates 3
  • High Estimate -0.20
  • Low Estimate -0.37
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +53.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.15 +12.68%
on 12/19/24
10.70 -35.22%
on 12/02/24
-1.43 (-17.11%)
since 11/20/24
3-Month
4.59 +50.82%
on 10/09/24
12.40 -44.11%
on 10/28/24
+0.45 (+6.94%)
since 09/20/24
52-Week
3.21 +115.89%
on 06/28/24
12.40 -44.11%
on 10/28/24
+1.53 (+28.33%)
since 12/20/23

Most Recent Stories

More News
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

Monte Rosa Therapeutics appointed Dr. Eric A. Hughes to its Board, enhancing R&D leadership for its molecular glue degrader pipeline.Quiver AI SummaryMonte Rosa Therapeutics, Inc. has announced the appointment...

GLUE : 6.93 (+6.45%)
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

GLUE : 6.93 (+6.45%)
Monte Rosa Therapeutics Announces Licensing Agreement with Novartis to Advance VAV1-Directed Molecular Glue Degrader MRT-6160

Monte Rosa Therapeutics and Novartis entered an exclusive license agreement to develop MRT-6160, targeting immune-mediated conditions.Quiver AI SummaryMonte Rosa Therapeutics, Inc. has finalized an exclusive...

GLUE : 6.93 (+6.45%)
Monte Rosa Therapeutics Announces Promising Preclinical Data for CDK2-Directed Molecular Glue Degrader MRT-9643 in HR-Positive/HER2-Negative Breast Cancer

Monte Rosa's MRT-9643 shows promise in treating HR-positive/HER2-negative breast cancer with superior selectivity and reduced toxicities.Quiver AI SummaryMonte Rosa Therapeutics announced promising preclinical...

GLUE : 6.93 (+6.45%)
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

GLUE : 6.93 (+6.45%)
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

GLUE : 6.93 (+6.45%)
Monte Rosa Therapeutics Announces Positive Interim Results from Phase 1/2 Study of MRT-2359 in MYC-Driven Solid Tumors

MRT-2359 shows favorable safety and effective GSPT1 degradation in Phase 1/2 study; Phase 2 dosing schedule recommended.Quiver AI SummaryMonte Rosa Therapeutics, Inc. announced positive interim results...

GLUE : 6.93 (+6.45%)
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

GLUE : 6.93 (+6.45%)
Monte Rosa Therapeutics CEO to Participate in Fireside Chat at 36th Annual Piper Sandler Healthcare Conference

Monte Rosa Therapeutics' CEO will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 3, 2024.Quiver AI SummaryMonte Rosa Therapeutics, Inc., a clinical-stage biotechnology...

GLUE : 6.93 (+6.45%)
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

GLUE : 6.93 (+6.45%)

Business Summary

Monte Rosa Therapeutics Inc. is a biotechnology company. It involved in developing a portfolio of novel small molecule precision medicines which employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 7.97
2nd Resistance Point 7.56
1st Resistance Point 7.24
Last Price 6.93
1st Support Level 6.51
2nd Support Level 6.10
3rd Support Level 5.78

See More

52-Week High 12.40
Fibonacci 61.8% 8.89
Fibonacci 50% 7.80
Last Price 6.93
Fibonacci 38.2% 6.72
52-Week Low 3.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar